Statistics from Altmetric.com
We read with interest the comments of Buchan and Manuel concerning our risedronate intervention trial in osteopenic patients with Crohn's disease.1 ,2
They stipulated that exclusion of patients with vitamin D deficiency limited the significance of the performed study, as this deficiency is frequently observed in Crohn's disease. It is however well known that replenishment of vitamin D (and calcium) in patients with vitamin D deficiency would lead to a rapid improvement of bone density, irrespective of any effect of risedronate. As assessment of a therapeutic effect of the latter was our primary study aim, we …
Correction notice The title of this letter has changed since published Online First.
Contributors AAvB, BIW and PL prepared the letter of response. All subsequent authors critically reviewed the letter and approved its contents.
Competing interests None.
Patient consent Obtained.
Provenance and peer review Not commissioned; internally peer reviewed.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.